Fig. 2.

Safety and efficacy outcomes in patients receiving/not receiving proton pump inhibitors (PPIs) at baseline: dabigatran 150 mg dual therapy vs warfarin triple therapy. For the comparison with 150 mg dabigatran dual therapy, elderly patients outside the USA are excluded. Hazard ratios (HRs) and 95% confidence intervals (CIs) from the unstratified Cox proportional hazard model. CRNMBE clinically relevant non-major bleeding event, DTE death/thromboembolic event, ISTH International Society on Thrombosis and Haemostasis, MBE major bleeding event